Group One Trading, L.P. Aurinia Pharmaceuticals Inc. Transaction History

Group One Trading, L.P.

  • $2.4 Billion
  • Q3 2024

A detailed history of Group One Trading, L.P. transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 350,413 shares of AUPH stock, worth $2.85 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
350,413
Holding current value
$2.85 Million
% of portfolio
0.11%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$5.32 - $7.33 $1.86 Million - $2.57 Million
350,413 New
350,413 $2.57 Million
Q1 2024

May 10, 2024
SELL
$4.93 - $9.31 $1.49 Million - $2.81 Million
-301,518 Reduced 44.42%
377,322 $1.89 Million
Q4 2023

Feb 14, 2024
BUY
$7.13 - $9.49 $673,485 - $896,406
94,458 Added 16.16%
678,840 $6.1 Million
Q3 2023

Nov 09, 2023
BUY
$7.77 - $12.27 $1.69 Million - $2.67 Million
217,289 Added 59.19%
584,382 $4.54 Million
Q2 2023

Aug 09, 2023
BUY
$8.96 - $11.69 $392,098 - $511,566
43,761 Added 13.53%
367,093 $3.55 Million
Q1 2023

May 12, 2023
BUY
$5.94 - $11.27 $40,011 - $75,914
6,736 Added 2.13%
323,332 $3.54 Million
Q4 2022

Feb 09, 2023
SELL
$4.11 - $8.14 $612,772 - $1.21 Million
-149,093 Reduced 32.02%
316,596 $1.37 Million
Q3 2022

Nov 09, 2022
SELL
$6.66 - $12.39 $13,659 - $25,411
-2,051 Reduced 0.44%
465,689 $3.5 Million
Q2 2022

Aug 11, 2022
BUY
$8.95 - $12.8 $749,965 - $1.07 Million
83,795 Added 21.82%
467,740 $4.7 Million
Q1 2022

May 12, 2022
BUY
$10.05 - $22.48 $3.57 Million - $7.99 Million
355,207 Added 1236.02%
383,945 $4.75 Million
Q4 2021

Feb 11, 2022
SELL
$17.78 - $33.08 $486,265 - $904,704
-27,349 Reduced 48.76%
28,738 $657,000
Q3 2021

Nov 12, 2021
SELL
$10.93 - $23.55 $2.47 Million - $5.31 Million
-225,564 Reduced 80.09%
56,087 $1.24 Million
Q2 2021

Aug 10, 2021
BUY
$10.0 - $14.52 $1.2 Million - $1.74 Million
120,178 Added 74.43%
281,651 $3.65 Million
Q1 2021

May 12, 2021
SELL
$12.3 - $18.73 $1.92 Million - $2.93 Million
-156,483 Reduced 49.22%
161,473 $2.1 Million
Q4 2020

Feb 10, 2021
SELL
$12.94 - $16.05 $325,272 - $403,448
-25,137 Reduced 7.33%
317,956 $4.4 Million
Q3 2020

Nov 12, 2020
BUY
$13.19 - $16.66 $974,239 - $1.23 Million
73,862 Added 27.43%
343,093 $5.05 Million
Q2 2020

Aug 13, 2020
BUY
$14.12 - $18.33 $719,512 - $934,041
50,957 Added 23.35%
269,231 $4.38 Million
Q1 2020

May 13, 2020
BUY
$11.34 - $21.46 $539,228 - $1.02 Million
47,551 Added 27.85%
218,274 $3.17 Million
Q4 2019

Feb 10, 2020
BUY
$3.88 - $21.42 $402,615 - $2.22 Million
103,767 Added 154.98%
170,723 $3.46 Million
Q3 2019

Nov 12, 2019
BUY
$5.34 - $6.59 $292,151 - $360,538
54,710 Added 446.76%
66,956 $358,000
Q2 2019

Aug 09, 2019
BUY
$6.05 - $6.75 $47,716 - $53,237
7,887 Added 180.94%
12,246 $81,000
Q1 2019

May 13, 2019
SELL
$6.06 - $7.64 $290,237 - $365,910
-47,894 Reduced 91.66%
4,359 $28,000
Q4 2018

Feb 06, 2019
SELL
$5.08 - $6.83 $321,238 - $431,901
-63,236 Reduced 54.75%
52,253 $356,000
Q3 2018

Nov 08, 2018
BUY
$5.27 - $6.64 $188,133 - $237,041
35,699 Added 44.74%
115,489 $767,000
Q2 2018

Aug 14, 2018
SELL
$5.06 - $6.36 $339,328 - $426,507
-67,061 Reduced 45.67%
79,790 $449,000
Q1 2018

May 11, 2018
SELL
$4.85 - $5.99 $390,007 - $481,679
-80,414 Reduced 35.38%
146,851 $762,000
Q4 2017

Feb 09, 2018
SELL
$4.53 - $7.09 $156,728 - $245,299
-34,598 Reduced 13.21%
227,265 $1.03 Million
Q3 2017

Nov 15, 2017
BUY
$5.71 - $6.9 $150,721 - $182,132
26,396 Added 11.21%
261,863 $1.64 Million
Q2 2017

Aug 14, 2017
BUY
N/A
235,467
235,467 $1.44 Million

Others Institutions Holding AUPH

# of Institutions
209
Shares Held
58.7M
Call Options Held
1.14M
Put Options Held
1.51M
View Full List

About Aurinia Pharmaceuticals Inc.

AUPH Quotes by TradingView
  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.15B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email